Verona Pharma Plc ADR (VRNA)

$106.91 +0.12 (0.11%)
Market Cap 8.75B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 872.73
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,871,900
Avg Vol 1,571,794
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 97%
Beta 0.05
Analysts Sell
Price Target $106.00

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
De12
De12 May. 22 at 5:33 PM
$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!
0 · Reply
stjernerogvann
stjernerogvann May. 19 at 2:32 PM
$SLS @yG19 is not wrong about these opportunities coming along so seldom. I got lucky that @Trainguy1 brought $VRNA to my attention - that was a no-brainer, too. But this one seems even more so... Getting this much insight into how a trial is going is rare. I hope that many retail people take advantage - at least in a small way.
1 · Reply
ShadowBull3745
ShadowBull3745 May. 15 at 6:48 PM
$CADL $CCXI $VRNA
0 · Reply
marked0ne
marked0ne May. 15 at 6:40 PM
$CADL i've been into a few awesome investor calls over the last few years ($VRNA , $CCXI) . But this is the best investors call i've heard. ever.
3 · Reply
Kingjake26
Kingjake26 May. 15 at 5:54 PM
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
4 · Reply
marked0ne
marked0ne May. 15 at 5:35 PM
$CADL damn, i really thought my position was big enough. But damn, my belly tells me BUY BUY BUY! I get some serious $VRNA vibes here!
1 · Reply
TwongStocks
TwongStocks May. 12 at 11:44 AM
$VRNA Some former VRNA execs join ACHV https://www.globenewswire.com/news-release/2026/05/12/3292696/0/en/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma.html Christopher Martin (former VRNA CCO) joined the Board of Directors. Mark Zappia joined as Senior Vice President, Commercial. He oversaw the commercial strategy for Ohtuvayre Jim Willis joined as Vice President of Sales and Sales Enablement. He led the Ohtuvayre national field force. “Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO and reflects our evolution into a commercial-stage organization,” said Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences. “Having anchored Verona Pharma’s U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch. We are addressing one of the largest preventable public health problems we know, and the experience this team brings positions Achieve to deliver cytisinicline to the patients who need it and the prescribers who care for them.”
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:26 PM
$VRNA I said BTFD ¯\_(ツ)_/¯
0 · Reply
BioStick123
BioStick123 May. 7 at 7:20 PM
$URGN $XBI $VRNA
0 · Reply
shopno
shopno May. 7 at 5:41 PM
$IOVA while I am pessimistic with management, specially the clown interim CEO, >=40% YoY growth for cell therapy is considered healthy / remarkable. $IOVA is not $MDGL or $VRNA — that investors should have expected >= 100% YoY growth at end of 2nd year of launch. That being said, upside till H1 2027 is very limited. Cheap options for 20027 may give some return if stock jumps $6-8 later this year with >= 40% YoY growth and >= 50% gross.
0 · Reply
Latest News on VRNA
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Oct 6, 2025, 4:05 PM EDT - 8 months ago

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Sep 24, 2025, 4:05 PM EDT - 8 months ago

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Sep 16, 2025, 6:00 AM EDT - 8 months ago

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Jul 12, 2025, 9:09 PM EDT - 11 months ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

MRK

Major deals involving U.S. drugmakers and biotechs over the past decade

Jul 9, 2025, 1:46 PM EDT - 11 months ago

Major deals involving U.S. drugmakers and biotechs over the past decade

MRK

Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 11 months ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK

Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 11 months ago

Two big reasons why buying Verona was crucial for Merck

Merck has struck a roughly $10 billion deal to buy Verona Pharma

Jul 9, 2025, 10:36 AM EDT - 11 months ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

MRK

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Jul 9, 2025, 8:13 AM EDT - 11 months ago

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Jul 9, 2025, 7:48 AM EDT - 11 months ago

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

MRK

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

Jul 9, 2025, 7:14 AM EDT - 11 months ago

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

MRK

Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 11 months ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK

Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 11 months ago

Merck to acquire Verona Pharma for $10 billion

MRK

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Jul 9, 2025, 6:30 AM EDT - 11 months ago

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

MRK

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Jul 9, 2025, 1:09 AM EDT - 11 months ago

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

MRK

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM LEGN

Verona Pharma Announces June 2025 Investor Conference Participation

May 21, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

May 6, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Mar 28, 2025, 7:00 AM EDT - 1 year ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 18, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Feb 13, 2025, 6:00 AM EST - 1 year ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Jan 7, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 19, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Announces December 2024 Investor Conference Participation

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 9, 2024, 8:23 AM EST - 1 year ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 2:00 AM EST - 1 year ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 21, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO GRDX

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Sep 5, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 25, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024, 9:03 AM EDT - 2 years ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 5:13 PM EDT - 2 years ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 26, 2024, 4:57 PM EDT - 2 years ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:15 AM EDT - 2 years ago

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

May 9, 2024, 7:00 AM EDT - 2 years ago

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

May 2, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 25, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Andrew Fisher Joins Verona Pharma as General Counsel

Mar 4, 2024, 2:00 AM EST - 2 years ago

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 2:00 AM EST - 2 years ago

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 2:00 AM EST - 2 years ago

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Michael Austwick Joins Verona Pharma as Non-Executive Director

Feb 1, 2024, 2:00 AM EST - 2 years ago

Michael Austwick Joins Verona Pharma as Non-Executive Director

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 2:00 AM EST - 2 years ago

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Jan 2, 2024, 2:00 AM EST - 2 years ago

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Nov 17, 2023, 2:00 AM EST - 2 years ago

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

De12
De12 May. 22 at 5:33 PM
$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!
0 · Reply
stjernerogvann
stjernerogvann May. 19 at 2:32 PM
$SLS @yG19 is not wrong about these opportunities coming along so seldom. I got lucky that @Trainguy1 brought $VRNA to my attention - that was a no-brainer, too. But this one seems even more so... Getting this much insight into how a trial is going is rare. I hope that many retail people take advantage - at least in a small way.
1 · Reply
ShadowBull3745
ShadowBull3745 May. 15 at 6:48 PM
$CADL $CCXI $VRNA
0 · Reply
marked0ne
marked0ne May. 15 at 6:40 PM
$CADL i've been into a few awesome investor calls over the last few years ($VRNA , $CCXI) . But this is the best investors call i've heard. ever.
3 · Reply
Kingjake26
Kingjake26 May. 15 at 5:54 PM
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
4 · Reply
marked0ne
marked0ne May. 15 at 5:35 PM
$CADL damn, i really thought my position was big enough. But damn, my belly tells me BUY BUY BUY! I get some serious $VRNA vibes here!
1 · Reply
TwongStocks
TwongStocks May. 12 at 11:44 AM
$VRNA Some former VRNA execs join ACHV https://www.globenewswire.com/news-release/2026/05/12/3292696/0/en/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma.html Christopher Martin (former VRNA CCO) joined the Board of Directors. Mark Zappia joined as Senior Vice President, Commercial. He oversaw the commercial strategy for Ohtuvayre Jim Willis joined as Vice President of Sales and Sales Enablement. He led the Ohtuvayre national field force. “Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO and reflects our evolution into a commercial-stage organization,” said Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences. “Having anchored Verona Pharma’s U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch. We are addressing one of the largest preventable public health problems we know, and the experience this team brings positions Achieve to deliver cytisinicline to the patients who need it and the prescribers who care for them.”
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:26 PM
$VRNA I said BTFD ¯\_(ツ)_/¯
0 · Reply
BioStick123
BioStick123 May. 7 at 7:20 PM
$URGN $XBI $VRNA
0 · Reply
shopno
shopno May. 7 at 5:41 PM
$IOVA while I am pessimistic with management, specially the clown interim CEO, >=40% YoY growth for cell therapy is considered healthy / remarkable. $IOVA is not $MDGL or $VRNA — that investors should have expected >= 100% YoY growth at end of 2nd year of launch. That being said, upside till H1 2027 is very limited. Cheap options for 20027 may give some return if stock jumps $6-8 later this year with >= 40% YoY growth and >= 50% gross.
0 · Reply
shopno
shopno May. 6 at 4:16 PM
$MDGL while the management fake hypes on 50% patients expansion for F2/F3 MASH, incremental patients declined QoQ. Last Quarter added ~7k patients, this quarter only 6k. While I invested both in $VRNA and $MDGL , the latter has been too poor performing in comparison — up only ~70% since fda approval while TTM revenue > $1.1B.
1 · Reply
Kingjake26
Kingjake26 Apr. 29 at 12:19 PM
$CADL I love what our CEO is doing is is building a strong business. Every day that goes buy it will cost large pharma more and more if they want this. The best part is if they don’t we will grow organically and be a multibillion dollar company in my opinion. This reminds me of $VRNA amazing management team
0 · Reply
De12
De12 Apr. 24 at 5:33 PM
$ADMA $CDTX $SWTX $VRNA $ADMA it’s Next!!
0 · Reply
BullriderNkg
BullriderNkg Apr. 23 at 8:41 AM
$VRNA As most Bulls miss OUR Verona . I just checked Q4 sales of Ohtuvayre 2025 for Merck were 178 Million. So 2026 it would have been a Billion dollar drug. I said it before management sold it too soon. Probably some big bonuses!!!
2 · Reply
De12
De12 Apr. 14 at 11:16 PM
$ADMA Druckenmiller had buyouts with $CDTX $SWTX $VRNA and Next will be $ADMA load Up!!
2 · Reply
De12
De12 Apr. 2 at 2:05 PM
$ADMA Druckenmiller had Buyouts with $VRNA $CDTX $SWTX next is $ADMA
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 31 at 1:07 PM
$VRNA have a good rest of the week ol friends
0 · Reply
moneybag888
moneybag888 Mar. 27 at 5:00 PM
$DNLI $45 to $65 buyout dejavu $VRNA
0 · Reply
LongLongStock
LongLongStock Mar. 24 at 8:05 AM
$VRNA I miss this stock
2 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 21 at 3:17 PM
$VRNA Miss you guys
2 · Reply
stjernerogvann
stjernerogvann Mar. 7 at 2:32 PM
$SLS it has been a couple of years since I have seen such a no-brainer investment. The last one was $VRNA which had great COPD data, a unique MOA, easy inhalable delivery, and a huge market. The market beat the share price down after approval and it was a great opportunity. In less than a year Merck bought the company for 8x. $SLS is more compelling: the increase in survival odds from single digits to ~70% will make GPS SOC for AML (and for MM I think) and market capture should be near 100% of applicable patients. And the label will expand. I would be shocked if $SLS is not bought out for at least 15X once results are published.
3 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 5 at 9:38 PM
$IOVA thank you IOVA, $CAPR (jump from December) and $VRNA Crossed $2M today only about 18 months after first crossing a Milli IOVA is on the road to double digits this year, hopefully more
5 · Reply